Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NYSE | Common Stock
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain.
It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F.
Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes.
The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | 3.92 Increased by +85.78% | 2.60 Increased by +50.77% |
| Apr 30, 24 | 2.58 Increased by +59.26% | 2.46 Increased by +4.88% |
| Feb 6, 24 | 2.49 Increased by +19.14% | 2.22 Increased by +12.16% |
| Nov 2, 23 | 0.10 Decreased by -94.95% | -0.13 Increased by +176.92% |
| Aug 8, 23 | 2.11 Increased by +68.80% | 1.98 Increased by +6.57% |
| Apr 27, 23 | 1.62 Decreased by -41.52% | 1.73 Decreased by -6.36% |
| Feb 2, 23 | 2.09 Decreased by -16.06% | 1.78 Increased by +17.42% |
| Nov 1, 22 | 1.98 Increased by +2.06% | 1.92 Increased by +3.13% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 11.44 B Increased by +20.43% | 970.30 M Increased by +1.79 K% | Increased by +8.48% Increased by +1.50 K% |
| Jun 30, 24 | 11.30 B Increased by +35.98% | 2.97 B Increased by +68.27% | Increased by +26.25% Increased by +23.75% |
| Mar 31, 24 | 8.77 B Increased by +25.98% | 2.24 B Increased by +66.77% | Increased by +25.58% Increased by +32.38% |
| Dec 31, 23 | 9.35 B Increased by +28.10% | 2.19 B Increased by +13.01% | Increased by +23.41% Decreased by -11.78% |
| Sep 30, 23 | 9.50 B Increased by +36.84% | -57.40 M Decreased by -103.95% | Decreased by -0.60% Decreased by -102.89% |
| Jun 30, 23 | 8.31 B Increased by +28.11% | 1.76 B Increased by +85.11% | Increased by +21.21% Increased by +44.49% |
| Mar 31, 23 | 6.96 B Decreased by -10.88% | 1.34 B Decreased by -29.32% | Increased by +19.32% Decreased by -20.69% |
| Dec 31, 22 | 7.30 B Decreased by -8.73% | 1.94 B Increased by +12.26% | Increased by +26.54% Increased by +22.99% |